[go: up one dir, main page]

MA33511B1 - Formulations orales solides et formes cristallines d'un inhibiteur de protéine d'apoptose - Google Patents

Formulations orales solides et formes cristallines d'un inhibiteur de protéine d'apoptose

Info

Publication number
MA33511B1
MA33511B1 MA34608A MA34608A MA33511B1 MA 33511 B1 MA33511 B1 MA 33511B1 MA 34608 A MA34608 A MA 34608A MA 34608 A MA34608 A MA 34608A MA 33511 B1 MA33511 B1 MA 33511B1
Authority
MA
Morocco
Prior art keywords
inhibitor
crystalline forms
solid oral
oral formulations
apoptosis protein
Prior art date
Application number
MA34608A
Other languages
Arabic (ar)
English (en)
Inventor
Jeewan Thakur
Dong Yang
Lili Feng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33511(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33511B1 publication Critical patent/MA33511B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline de (s)-n-((s)-1-cyclohexyl-2-{(s)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-éthyl)-2-méthylamino-propionamide, et des sels et hydrates de celle-ci. La présente invention concern
MA34608A 2009-08-12 2012-02-07 Formulations orales solides et formes cristallines d'un inhibiteur de protéine d'apoptose MA33511B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
PCT/EP2010/061679 WO2011018474A1 (fr) 2009-08-12 2010-08-11 Formulations orales solides et formes cristallines d'un inhibiteur de protéine d'apoptose

Publications (1)

Publication Number Publication Date
MA33511B1 true MA33511B1 (fr) 2012-08-01

Family

ID=42937834

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34608A MA33511B1 (fr) 2009-08-12 2012-02-07 Formulations orales solides et formes cristallines d'un inhibiteur de protéine d'apoptose

Country Status (24)

Country Link
US (4) US8623385B2 (fr)
EP (1) EP2464644A1 (fr)
JP (3) JP2013501751A (fr)
KR (2) KR20180020315A (fr)
CN (2) CN105646471A (fr)
AR (1) AR077869A1 (fr)
AU (4) AU2010283748A1 (fr)
BR (1) BR112012003118A2 (fr)
CA (1) CA2769616A1 (fr)
CL (1) CL2012000349A1 (fr)
CO (1) CO6612189A2 (fr)
IL (1) IL217760A0 (fr)
IN (1) IN2012DN00858A (fr)
MA (1) MA33511B1 (fr)
MX (2) MX2012001844A (fr)
MY (1) MY160475A (fr)
PE (2) PE20121132A1 (fr)
PH (1) PH12014501890B1 (fr)
RU (1) RU2671196C1 (fr)
SG (1) SG177713A1 (fr)
TN (1) TN2012000026A1 (fr)
TW (1) TWI607006B (fr)
WO (1) WO2011018474A1 (fr)
ZA (1) ZA201200390B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182418A1 (fr) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugués comprenant des inhibiteurs de ripk2
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
WO2021220178A1 (fr) 2020-04-29 2021-11-04 Cominnex Zrt. Antagonistes d'iap et leurs applications thérapeutiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502861A (ja) * 2001-08-10 2005-01-27 サイミックス テクノロジーズ， インコーポレイテッド 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム
CA2491041A1 (fr) 2002-07-02 2004-01-15 Novartis Ag Inhibiteurs peptidiques de la liaison de la proteine smac avec les proteines inhibitrices de l'apoptose (iap)
SG152225A1 (en) * 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
AU2017254950B2 (en) 2018-09-20
US20140093570A1 (en) 2014-04-03
RU2671196C1 (ru) 2018-10-30
CO6612189A2 (es) 2013-02-01
CA2769616A1 (fr) 2011-02-17
AR077869A1 (es) 2011-09-28
PH12014501890A1 (en) 2015-09-14
RU2012108931A (ru) 2013-09-27
MX2012001844A (es) 2012-02-29
US9540363B2 (en) 2017-01-10
US20120128742A1 (en) 2012-05-24
AU2017254950A1 (en) 2017-11-23
WO2011018474A1 (fr) 2011-02-17
CN102471331B (zh) 2016-01-13
MX351274B (es) 2017-10-06
SG177713A1 (en) 2012-02-28
KR20180020315A (ko) 2018-02-27
IL217760A0 (en) 2012-03-29
CL2012000349A1 (es) 2012-09-07
US20180370960A1 (en) 2018-12-27
JP2013501751A (ja) 2013-01-17
US20170081319A1 (en) 2017-03-23
JP2018172403A (ja) 2018-11-08
CN105646471A (zh) 2016-06-08
ZA201200390B (en) 2012-10-31
JP2016179976A (ja) 2016-10-13
AU2010283748A1 (en) 2012-02-09
PE20121132A1 (es) 2012-09-04
CN102471331A (zh) 2012-05-23
BR112012003118A2 (pt) 2016-02-23
MY160475A (en) 2017-03-15
KR20120048008A (ko) 2012-05-14
PH12014501890B1 (en) 2015-09-14
US8623385B2 (en) 2014-01-07
TWI607006B (zh) 2017-12-01
TN2012000026A1 (en) 2013-09-19
TW201118091A (en) 2011-06-01
WO2011018474A8 (fr) 2011-09-22
PE20170777A1 (es) 2017-07-04
AU2014213533A1 (en) 2014-09-04
US10093665B2 (en) 2018-10-09
AU2016203145A1 (en) 2016-06-02
EP2464644A1 (fr) 2012-06-20
IN2012DN00858A (fr) 2015-07-10

Similar Documents

Publication Publication Date Title
IL236883A0 (en) Intermediate compounds for the preparation of (1-(s))-n-(s-cyclohexyl-2-{(4)-2-(s-(fluoro-benzoyl)-thiazol-2-yl]pyrrolidine-1-yl}-2 -oxo-ethyl)-2-methylamino-propionamide
EP1967207A4 (fr) Inhibiteur de l'induction des cellules t cytotoxiques
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
IL176489A0 (en) Composition for removal of residue comprising cationic salts and methods using same
FR2892634B3 (fr) Procedes de reduction du dose dumping induit par l'alcool pour des formes posologiques orales d'opioides a liberation prolongee
EP1962945A4 (fr) Evaluation de couplage d'electrode pour ablation tissulaire
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
IL192242A0 (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
CL2007003158A1 (es) Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
ZA200806778B (en) N-Hydroxyacrylamide compounds
MA33511B1 (fr) Formulations orales solides et formes cristallines d'un inhibiteur de protéine d'apoptose
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
IL198089A0 (en) An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure
EP2123628A4 (fr) Procédé de préparation de milnacipran optiquement pur et de ses sels pharmaceutiquement acceptables
MA31259B1 (fr) Formes solides d'un inhibiteur des kinases raf
ZA200801592B (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
EP1846024A4 (fr) Mutants mycobacteriens afectant l'apoptose chez l'hôte
AR059327A1 (es) Monohidrato de rimonabant su procedimiento de preparacion y composiciones farmaceuticas que lo contienen
ATE503473T1 (de) 3-(2,2,2-trimethylhydrazinium) propionat-salze zur behandlung des myokardinfarktes
EP1909820A4 (fr) Modulation de l'apoptose des cellules de la granulosa
MY150698A (en) Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
ITBO20040735A1 (it) Unita' per l'acquisizione di immagini radiografiche dentali
HU0500145D0 (en) Composition for the treatment of oral diseases